KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Account Payables: 2017-2024

Historic Change in Account Payables for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to $2.8 million.

  • Aquestive Therapeutics' Change in Account Payables fell 169.62% to -$1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.9 million, marking a year-over-year increase of 415.84%. This contributed to the annual value of $2.8 million for FY2024, which is 372.75% up from last year.
  • As of FY2024, Aquestive Therapeutics' Change in Account Payables stood at $2.8 million, which was up 372.75% from -$1.0 million recorded in FY2023.
  • In the past 5 years, Aquestive Therapeutics' Change in Account Payables ranged from a high of $2.8 million in FY2024 and a low of -$5.2 million during FY2020.
  • Over the past 3 years, Aquestive Therapeutics' median Change in Account Payables value was $1.6 million (recorded in 2022), while the average stood at $1.1 million.
  • As far as peak fluctuations go, Aquestive Therapeutics' Change in Account Payables slumped by 162.46% in 2023, and later surged by 372.75% in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' Change in Account Payables stood at -$5.2 million in 2020, then spiked by 123.63% to $1.2 million in 2021, then skyrocketed by 33.31% to $1.6 million in 2022, then tumbled by 162.46% to -$1.0 million in 2023, then surged by 372.75% to $2.8 million in 2024.